{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T17:10:41Z","timestamp":1732900241965,"version":"3.30.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,29]]},"DOI":"10.7759\/cureus.74760","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T16:35:36Z","timestamp":1732898136000},"source":"Crossref","is-referenced-by-count":0,"title":["Characterization of Acute Myeloid Leukemia With RUNX1\/RUNX1T1 Gene Rearrangement: Clinical, Hematological, and Morphological Features"],"prefix":"10.7759","author":[{"given":"Sadaf","family":"Maqbool","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iqra","family":"Maqbool","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marya","family":"Yousaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birya","family":"Farooqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirza Zeeshan","family":"Sikandar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ridha","family":"Zainab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khush","family":"Bakht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mishal","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000178","article-title":"Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations","volume":"3","author":"H\u00f6llein A","year":"2019","unstructured":"H\u00f6llein A, Nadarajah N, Meggendorfer M, Jeromin S, Kern W, Haferlach C, Haferlach T. Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations. Hemasphere. 2019, 3:e178. 10.1097\/HS9.0000000000000178","journal-title":"Hemasphere"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0414-2","article-title":"The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia","volume":"10","author":"Qin YZ","year":"2017","unstructured":"Qin YZ, Wang Y, Xu LP, et al.. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. J Hematol Oncol. 2017, 10:44. 10.1186\/s13045-017-0414-2","journal-title":"J Hematol Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-01973-x","article-title":"Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t (8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation","volume":"58","author":"Kong J","year":"2023","unstructured":"Kong J, Zheng FM, Wang ZD, et al.. Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t (8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2023, 58:777-83. 10.1038\/s41409-023-01973-x","journal-title":"Bone Marrow Transplant"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01371.x","article-title":"Persistent altered fusion transcript splicing identifies RUNX1-RUNX1T1+ AML patients likely to relapse","volume":"84","author":"Ommen HB","year":"2010","unstructured":"Ommen HB, Ostergaard M, Yan M, Braendstrup K, Zhang DE, Hokland P. Persistent altered fusion transcript splicing identifies RUNX1-RUNX1T1+ AML patients likely to relapse. Eur J Haematol. 2010, 84:128-32. 10.1111\/j.1600-0609.2009.01371.x","journal-title":"Eur J Haematol"},{"key":"ref5","article-title":"The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias","volume":"82","author":"Lo Coco F","year":"1997","unstructured":"Lo Coco F, Pisegna S, Diverio D. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias. Haematologica. 1997, 82:364-70.","journal-title":"Haematologica"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1829","article-title":"Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia","volume":"11","author":"Stams WA","year":"2005","unstructured":"Stams WA, den Boer ML, Beverloo HB, Meijerink JP, van Wering ER, Janka-Schaub GE, Pieters R. Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia. Clin Cancer Res. 2005, 11:2974-80. 10.1158\/1078-0432.CCR-04-1829","journal-title":"Clin Cancer Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-016-0110-6","article-title":"Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation","volume":"35","author":"Qin YZ","year":"2016","unstructured":"Qin YZ, Wang Y, Zhu HH, et al.. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation. Chin J Cancer. 2016, 35:46. 10.1186\/s40880-016-0110-6","journal-title":"Chin J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-018-0716-7","article-title":"Next-generation sequencing-based genetic landscape and its clinical implications for Chinese acute myeloid leukemia patients","volume":"18","author":"Cao XX","year":"2018","unstructured":"Cao XX, Cai H, Mao YY, Wu Q, Zhang L, Zhou DB, Li J. Next-generation sequencing-based genetic landscape and its clinical implications for Chinese acute myeloid leukemia patients. Cancer Cell Int. 2018, 18:215. 10.1186\/s12935-018-0716-7","journal-title":"Cancer Cell Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.6652","article-title":"RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures","volume":"30","author":"Mendler JH","year":"2012","unstructured":"Mendler JH, Maharry K, Radmacher MD, et al.. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. J Clin Oncol. 2012, 30:3109-18. 10.1200\/JCO.2011.40.6652","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2021.02.015","article-title":"Comparison of genetic mutations in myelodysplastic syndrome and acute myeloid leukemia (Article in Chinese)","volume":"42","author":"Chen WS","year":"2021","unstructured":"Chen WS, Zhang ML, Han B. Comparison of genetic mutations in myelodysplastic syndrome and acute myeloid leukemia (Article in Chinese). Zhonghua Xue Ye Xue Za Zhi. 2021, 42:171-6. 10.3760\/cma.j.issn.0253-2727.2021.02.015","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23696","article-title":"Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA","volume":"89","author":"Duployez N","year":"2014","unstructured":"Duployez N, Nibourel O, Marceau-Renaut A, et al.. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA. Am J Hematol. 2014, 89:610-5. 10.1002\/ajh.23696","journal-title":"Am J Hematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1159\/000323425","article-title":"Acute myeloid leukemia with a RUNX1-RUNX1T1 t(1;21;8)(q21;q22;q22) novel variant: a case report and review of the literature","volume":"125","author":"Kim H","year":"2011","unstructured":"Kim H, Moon HW, Hur M, Yun YM, Lee MH. Acute myeloid leukemia with a RUNX1-RUNX1T1 t(1;21;8)(q21;q22;q22) novel variant: a case report and review of the literature. Acta Haematol. 2011, 125:237-41. 10.1159\/000323425","journal-title":"Acta Haematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03368-4","article-title":"Comprehensive insights into AML relapse: genetic mutations, clonal evolution, and clinical outcomes","volume":"24","author":"Kim N","year":"2024","unstructured":"Kim N, Hahn S, Choi YJ, et al.. Comprehensive insights into AML relapse: genetic mutations, clonal evolution, and clinical outcomes. Cancer Cell Int. 2024, 24:174. 10.1186\/s12935-024-03368-4","journal-title":"Cancer Cell Int"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-023-01196-2","article-title":"Combination of eriocalyxin B and homoharringtonine exerts synergistic anti-tumor effects against t(8;21) AML","volume":"45","author":"Lei YC","year":"2024","unstructured":"Lei YC, Chen XJ, Dai YT, et al.. Combination of eriocalyxin B and homoharringtonine exerts synergistic anti-tumor effects against t(8;21) AML. Acta Pharmacol Sin. 2024, 45:633-45. 10.1038\/s41401-023-01196-2","journal-title":"Acta Pharmacol Sin"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000168","article-title":"An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1","volume":"4","author":"Al-Harbi S","year":"2020","unstructured":"Al-Harbi S, Aljurf M, Mohty M, Almohareb F, Ahmed SO. An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1. Blood Adv. 2020, 4:229-38. 10.1182\/bloodadvances.2019000168","journal-title":"Blood Adv"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2020.11.005","article-title":"The RUNX1\/RUNX1T1 network: translating insights into therapeutic options","volume":"94","author":"Swart LE","year":"2021","unstructured":"Swart LE, Heidenreich O. The RUNX1\/RUNX1T1 network: translating insights into therapeutic options. Exp Hematol. 2021, 94:1-10. 10.1016\/j.exphem.2020.11.005","journal-title":"Exp Hematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.21037\/tp-23-536","article-title":"The efficacy of homoharringtonine in pediatric acute myeloid leukemia: findings from the Chinese Children's Leukemia Group-AML 2015 Study","volume":"13","author":"Catueno S","year":"2024","unstructured":"Catueno S, Haddad FG, Cuglievan B. The efficacy of homoharringtonine in pediatric acute myeloid leukemia: findings from the Chinese Children's Leukemia Group-AML 2015 Study. Transl Pediatr. 2024, 13:376-9. 10.21037\/tp-23-536","journal-title":"Transl Pediatr"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030483","article-title":"Revealing the mysteries of acute myeloid leukemia: from quantitative PCR through next-generation sequencing and systemic metabolomic profiling","volume":"11","author":"Panuzzo C","year":"2022","unstructured":"Panuzzo C, Jovanovski A, Ali MS, Cilloni D, Pergolizzi B. Revealing the mysteries of acute myeloid leukemia: from quantitative PCR through next-generation sequencing and systemic metabolomic profiling. J Clin Med. 2022, 11:483. 10.3390\/jcm11030483","journal-title":"J Clin Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01952-w","article-title":"AML1\/ETO and its function as a regulator of gene transcription via epigenetic mechanisms","volume":"40","author":"Rejeski K","year":"2021","unstructured":"Rejeski K, Duque-Afonso J, L\u00fcbbert M. AML1\/ETO and its function as a regulator of gene transcription via epigenetic mechanisms. Oncogene. 2021, 40:5665-76. 10.1038\/s41388-021-01952-w","journal-title":"Oncogene"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/314194-characterization-of-acute-myeloid-leukemia-with-runx1runx1t1-gene-rearrangement-clinical-hematological-and-morphological-features","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T16:35:39Z","timestamp":1732898139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/314194-characterization-of-acute-myeloid-leukemia-with-runx1runx1t1-gene-rearrangement-clinical-hematological-and-morphological-features"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.74760","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,29]]}}}